Rheumatoid ArthritisPhase 4NCT01331837
A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors
A Phase 4 study testing Etanercept and Tocilizumab in people with Rheumatoid Arthritis, run by Hoffmann-La Roche at 428 sites in 31 countries.
Trial summary
This randomized, open-label, parallel-group, multicenter study will evaluate the rate of cardiovascular events with tocilizumab in comparison to etanercept in participants with rheumatoid arthritis (RA). Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Rheumatoid Arthritis
- What is being tested?
- Etanercept and Tocilizumab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 3,080 participants
- Where
- 428 sitesin 31 countries
- Study dates
- 2 Aug 2011to 25 Mar 2016
- Phase
- Phase 4
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants with moderate to severe RA of greater than or equal to (>=6) months duration
- Inadequate response to at least one non-biologic DMARD
- Positive for Rheumatoid Factor (RF) and/or anti-cyclic citrullinated peptide (CCP) antibodies at screening
- Have C-reactive protein (CRP) greater than (>) 0.3 milligrams per deciliter (mg/dL) at screening or at the baseline visit
- Swollen joint count (SJC) >=8 (66 joint count) and tender joint count (TJC) >= 8 (68 joint count) during screening or at the baseline visit
- History of Coronary Heart Disease (CHD) or presence of one or more additional CHD risk factors, including current cigarette smoking, hypertension, low High Density Lipoprotein (HDL) cholesterol, family history of premature CHD, diabetes, presence of extra-articular disease associated with rheumatoid arthritis
- At the time of randomization, will have discontinued infliximab, adalimumab, golimumab, or certolizumab for >= 4 weeks
Who cannot join
- Major surgery (including joint surgery or coronary revascularization) within 8 weeks prior to screening or planned major surgery within 1 year of study start
- Rheumatic autoimmune disease other than RA
- History of or current inflammatory joint disease other than RA
- Current or recent (within past 3 months) evidence of serious uncontrolled concomitant cardiovascular or cerebrovascular disease (myocardial infarction, revascularization, stroke, transient ischemic attack, or acute coronary syndrome)
- Current or previous (within the past 2 years) evidence of serious uncontrolled concomitant pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine (including uncontrolled diabetes mellitus) or gastrointestinal disease
- Uncontrolled disease states, such as asthma or inflammatory bowel disease where flares are commonly treated with oral or parenteral corticosteroids
Show all 26Show fewer
- Pre-existing central nervous system demyelinating or seizure disorders
- History of diverticulitis, diverticulosis requiring treatment or other lower gastrointestinal tract conditions that might predispose to perforations
- Current liver disease as determined by the investigator; a history of asymptomatic elevations in liver function tests (LFTs) is not considered an exclusion
- Active current infection or history of recurrent bacterial, viral, fungal, mycobacterial or other infections, including but not limited to tuberculosis and atypical mycobacterial disease, hepatitis B and C, and herpes zoster, but excluding fungal infections of nail beds
- Any major episode of infection requiring hospitalization or treatment with IV antibiotics within four weeks of screening or oral antibiotics within two weeks prior to screening visit
- Active tuberculosis (TB) requiring treatment within 3 years prior to baseline
- Latent TB diagnosed during screening that has not been appropriately treated
- Primary or secondary immunodeficiency (history of or currently active)
- Moderate to severe heart failure
- Evidence of active malignant disease, malignancies diagnosed within the previous 10 years (including hematologic malignancies and solid tumors, except basal cell carcinoma of the skin that has been excised and cured), or breast cancer diagnosed within the previous 20 years
- Breast feeding mothers
- History of alcohol, drug or chemical abuse within the 6 months prior to screening
- Participants with lack of peripheral venous access
- Participants with a history of allergic reactions to latex
- Previous treatment with non-tumor necrosis factor (non-TNF)-inhibitor biologic therapy
- Treatment with any investigational agent within 4 weeks of screening visit
- Treatment with any cell depleting therapies within 1 year of baseline
- Treatment with IV gamma globulin, plasmapheresis or Prosorba column within 6 months of baseline visit
- Immunization with a live/attenuated vaccine within 4 weeks prior to baseline visit
- Any previous treatment with alkylating agents, such as cyclophosphamide or chlorambucil, or with total lymphoid irradiation
Trial locations and contacts
428 sites in 31 countries.
428 sites in 31 countries
United States143 sites
Albuquerque Center For Rheumatology
Albuquerque, New Mexico, 87102
Amarillo Center For Clinical Research
Amarillo, Texas, 79124
Asheville Arthritis & Osteoporosis Center, PA
Asheville, North Carolina, 28803
Emory Uni ; Division of Rheumatology
Atlanta, Georgia, 30303
Arthritis & Rheumatology of Georgia
Atlanta, Georgia, 30342
Rheumatology Associates of Baltimore
Baltimore, Maryland, 21286
Rheum & Pulmonary Clinic
Beckley, West Virginia, 25801
Summit Medical Group
Berkeley Heights, New Jersey, 07922
Uni Of Alabama,Birmingham; Medicine - Rheumatology
Birmingham, Alabama, 35294
Sonora Clinical Research
Boise, Idaho, 83702
St. Luke's Intermountain Research Center
Boise, Idaho, 83702
Selah Medical Ctr
Boise, Idaho, 83704
Graves Gilbert Clinic
Bowling Green, Kentucky, 42101
ZASA Clinical Research
Boynton Beach, Florida, 33472
Joao Nascimento
Bridgeport, Connecticut, 06606
Arthritis & Osteoporosis Medical Associates, Pllc
Brooklyn, New York, 11201
SUNY Downstate Medical Center.
Brooklyn, New York, 11203
Arthritis and Rheumatic Disease Associates
Burke, Virginia, 22015
Joint & Muscle Research Institute
Charlotte, North Carolina, 28204
Carolina Bone & Joint P.A.
Charlotte, North Carolina, 28210
University of Illinois at Chicago
Chicago, Illinois, 60612
Apex Medical Research, AMR, Inc.
Chicago, Illinois, 60616
Cincinnati Rheumatic Disease Study Group
Cincinnati, Ohio, 45219
Mountain State Clinical Research
Clarksburg, West Virginia, 26301
University Hospitals Case Medical Center
Cleveland, Ohio, 44109
Coeur D'Alene Arthritis Clinic
Coeur d'Alene, Idaho, 83814
Arthritis Assoc & Osteoporosis; Ctr of Colorado Springs
Colorado Springs, Colorado, 80920
Columbia Arthritis Center (Partnership Practice)
Columbia, South Carolina, 29204
Ohio State Univ Med Center
Columbus, Ohio, 43210
Columbus Arthritis Center
Columbus, Ohio, 43215
DC Health Clinic
Coral Gables, Florida, 33134
Adriana Pop-Moody MD Clinic PA
Corpus Christi, Texas, 78404
Samy Metyas, MD, Inc
Covina, California, 91723
Metroplex Clinical Research
Dallas, Texas, 75231
Tsai, Yong
Daytona Beach, Florida, 32117
North Georgia Rheumatology
Duluth, Georgia, 30096
Altoona Center For Clinical Research
Duncansville, Pennsylvania, 16635
Durham Rheumatology
Durham, North Carolina, 27704
St. Paul Rheumatology
Eagan, Minnesota, 55121
Phase Iii Clinical Research
Fall River, Massachusetts, 02720
University of Connecticut Health Center
Farmington, Connecticut, 06030
Hurley Research Center
Flint, Michigan, 48503
Jackson Arthritis Clinic
Flowood, Mississippi, 39232
Northern Indiana Research Alliance
Fort Wayne, Indiana, 46804
Leading Edge Research, PA; Office of Dr. Burbano
Fort Worth, Texas, 76109
Arizona Arthritis & Rheumatology Associates, P.C.
Glendale, Arizona, 85306
Osteoporosis & Clinical Trials Center
Hagerstown, Maryland, 21740
Arthritis & Osteoporosis Center Pc
Hamden, Connecticut, 06518
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033
PMG Research of Hickory LLC
Hickory, North Carolina, 28602
Rheumatic Disease Clin Res Ctr
Houston, Texas, 77004
Houston Inst. For Clinical Research
Houston, Texas, 77074
Talbert Medical Group
Huntington Beach, California, 92646
Rheumatology Associates of North Alabama
Huntsville, Alabama, 35801
Ilumina Clinical Associates
Indiana, Pennsylvania, 15701
Diagnostic Rheumatology & Research
Indianapolis, Indiana, 46227
Jacksonville Center For Clinical Research
Jacksonville, Florida, 32216
NEA Baptist Clinic
Jonesboro, Arkansas, 72401
Rheumatology, P.C.; Medical Arts Building
Kalamazoo, Michigan, 49009
Glacier View Research Institute
Kalispell, Montana, 59901
Apex Clinical Research
Kennewick, Washington, 99336
Allergy & Rheumatology Medical Clinic, Inc
La Jolla, California, 92037
Advanced Rheumatology, PC
Lansing, Michigan, 48910
Arthritis and Osteoporosis Associates of New Mexico
Las Cruces, New Mexico, 88011
Advanced Biomedical Research of America
Las Vegas, Nevada, 89123
Innovative Health Research
Las Vegas, Nevada, 89128
Dartmouth-Hitchcock Medical Center, Rheumatology 5C
Lebanon, New Hampshire, 03756
PMA Medical Specialists
Limerick, Pennsylvania, 19468
OrthoArkansas; Orthopedics & Sports Medicine
Little Rock, Arkansas, 72205
Valerius Medical Group
Los Alamitos, California, 90720
Ramesh Gupta - PP
Memphis, Tennessee, 38119
Idaho Arthritis Center
Meridian, Idaho, 83642
Southwest Rheumatology
Mesquite, Texas, 75150
Pharmax Research Clinic Inc.
Miami, Florida, 33126
Va Medical Center
Minneapolis, Minnesota, 55417
Trinity Health Center
Minot, North Dakota, 58701
Clinical Interventions Research Institute
Mission Viejo, California, 92692
Arthritis & Diabetes Clinic, Inc
Monroe, Louisiana, 71203
Dr. Brigid Freyne, MD
Murrieta, California, 92563
South Carolina Research Center
Myrtle Beach, South Carolina, 29572
Nashua Rheumatology - Foundation Medical Partners
Nashua, New Hampshire, 03060
Ochsner Health System
New Orleans, Louisiana, 70121
Sentara Medical Group
Norfolk, Virginia, 23510
DiGiovanna Inst for Med Ed&Res
North Massapequa, New York, 11758
Lynn Health Science Institute
Oklahoma City, Oklahoma, 73112
Southern Tier Arthritis & Rheumatism
Olean, New York, 14760
Univ of Nebraska Medical Ctr
Omaha, Nebraska, 68198
Arthritis/Osteoporosis Treatment Center
Orange Park, Florida, 32073
Research Integrity
Owensboro, Kentucky, 42303
Arthritis Rsrch of Florida, Inc.
Palm Harbor, Florida, 34684
Arizona Arthritis & Rheumatology Research, Pllc
Paradise Valley, Arizona, 85253
Baptist Hospital Clinical Research
Pensacola, Florida, 32501
Sun Valley Arthritis Center
Peoria, Arizona, 85381
Methodist Medical Center of Ilinois
Peoria, Illinois, 61602
Pivotal Clinical Research, Llc
Perkasie, Pennsylvania, 18944
Northern Michigan Regional Hospital
Petoskey, Michigan, 49770
Arthritis Group
Philadelphia, Pennsylvania, 19152
Valley Arthritis Care
Phoenix, Arizona, 85027
University of Pittsburgh Medical Center Health System; Infectious Disease
Pittsburgh, Pennsylvania, 15213-2582
Sharp Rees-Stealy Medical Group
Poway, California, 92064
Arthritis Centre; Suite 103
Racine, Wisconsin, 53406
Shanahan Rheumatology & Immunology, PLLC
Raleigh, North Carolina, 27617
Leading Edge Research, PA; Office of Dr. Burbano
Richardson, Texas, 75080
Mayo Clinic Rochester
Rochester, Minnesota, 55905
Harbin Clinic
Rome, Georgia, 30165
Texas Arthritis Research Center
San Antonio, Texas, 78217
San Diego Arthritis Med Clnc
San Diego, California, 92108
Purushotham & Akther Kotha Inc
San Diego, California, 92120
C Michael Neuwelt MD Inc
San Leandro, California, 94578
Specialty Medical Clinic and Research Center
Sanford, North Carolina, 27330
Pacific Arthritis Ctr Med Grp
Santa Maria, California, 93454
Orrin M. Troum, Md
Santa Monica, California, 90404
Lovelace Scientific Resources
Sarasota, Florida, 34292
St. Joseph'S/Candler Health System, Inc.; Office of Research
Savannah, Georgia, 31405
Advanced Arthritis Care & Research
Scottsdale, Arizona, 85258
Seattle Rheumatology Associates
Seattle, Washington, 98104
Memorial Medical Group Clinical Research
South Bend, Indiana, 46601
Centre for Arthritis and Rheumatic Diseases
South Miami, Florida, 33143
Pinellas Medical Research, LLC
St. Petersburg, Florida, 33708
Arthritis Health Associates; Clinical Research
Syracuse, New York, 13210
Office of George Krick, Md
Tacoma, Washington, 98405
SW Florida Clinical Research
Tampa, Florida, 33609
Healthpoint Medical group, Inc
Tampa, Florida, 33614
Rheumatology Associates Of New Jersey
Teaneck, New Jersey, 07666
Clinical Research Source, Inc.
Toledo, Ohio, 43606
Toledo Clinic
Toledo, Ohio, 43623
Harbor UCLA Medical Center
Torrance, California, 90509
Camp Lowell Medical Specialists
Tucson, Arizona, 85715
The University of Arizona
Tucson, Arizona, 85724
North Mississippi Med Clinics, Inc.
Tupelo, Mississippi, 38801
Clinical and Translational Research Center of Alabama, PC
Tuscaloosa, Alabama, 35406
Inland Rheumatology; Clinical Trials, Inc.
Upland, California, 91786
Arthritis Rheumatic & Back Disease Associates
Voorhees Township, New Jersey, 08043
Arthritis & Osteoporosis Clinic
Waco, Texas, 76710
Brown Clinic
Watertown, South Dakota, 57201
Allegheny Rheumatology
Wexford, Pennsylvania, 15090
Center For Rheumatology & Bone Research
Wheaton, Maryland, 20902
Medvin Clinical Research
Whittier, California, 90606
Carolina Arthritis Associates, Pa
Wilmington, North Carolina, 28401
UMass Memorial Medical Center
Worcester, Massachusetts, 01605
Clinical Pharmacology Study Group
Worcester, Massachusetts, 01610
Clinical Research Center of Reading
Wyomissing, Pennsylvania, 19610
Pennsylvania Regional Center for Arthritis and Osteoporosis Research
Wyomissing, Pennsylvania, 19610
Mexico23 sites
Hospital Christus Muguerza del Parque; Reumatologia
Chihuahua City, 31000
Hospital CIMA Chihuahua; Reumatologia
Chihuahua City, 31238
Hospital Privado San Jose de Ciudad Obregon SA de CV
Ciudad Obregón, 85000
Private Practice Dr. Cortes
Cuernavaca, 62270
Centro de Investigación de Tratamientos Innovadores de Sinaloa (CITI)
Culiacán, Sinaloa, 80000
RM pharma specialist SA de CV
Delegacion Benito Juarez, 03100
Mentrials S.A. de C.V
Distrito Federal, 06600
Centro de Investigacion y Atencion Integral Durango CIAID
Durango, 34080
Mundo Fisico
Guadalajara, 44500
Clinica Hospital Angeles Chapalita
Guadalajara, 45040
Unidad de Atencion Medica e Investigacion en Salud S.C.
Mérida, Yucatán, 97000
Centro de Investigacion en Enfermedades Reumaticas y Osteoporosis
Mexicali, 21100
Mexico Centre for Clinical Research
México, 03100
Comite Mexicano Para la Prevencion de Osteoporosis AC
México, 06100
Inst. Mexicano de Investigacion Clinica
Mexico City, 06700
Hospital Mocel
Mexico City, 11850
Instituto Nacional de Cardiologia Ignacio Chavez
Mexico City, 14080
Cliditer SA de CV
Miexico City, 06700
Hospital Universitario de Saltillo
Saltillo, 25000
Centro de Alta Especialidad en Reumatología e Investigación del Potosí, S.C.
San Luis Potosí City, 78200
Hospital Central Dr. Ignacio Morones Prieto
San Luis Potosi S.l.p., 78240
Centro de Investigacion del Noroeste SC
Tijuana, Estado de Baja California, 22010
Unidad de Enfermedades Reumaticas y Cronicodegenerativas
Torreón, 27000
Argentina21 sites
Centro de Investigaciones Reumatologicas y Osteologicas
Buenos Aires, 1111
Organizacion Medica de Investigacion
Buenos Aires, C1015ABO
CEIM Consultorios Especializados en Investigaciones Médicas
Buenos Aires, C1117ABK
APRILLUS
Buenos Aires, C1194AAO
Instituto centenario
Buenos Aires, C1204AAD
Fundación CIDEA
Buenos Aires, C1425DTG
Atencion Integral En Reumatologia Buenos Aires
Buenos Aires, C1426AAL
CEMIC
Buenos Aires, C1431FWO
Hospital General de Agudos Dr. J. M. Ramos Mejia
Ciudad Autonoma Buenos Aires, C1221ADC
Hospital Britanico de Buenos Aires
Ciudad Autonoma Buenos Aires, C1284AEB
Instituto Reumatológico Strusberg
Córdoba, 5000
Hospital Italiano de Cordoba
Córdoba, X5004BAL
Hospital Privado Cordoba
Cordoba Pcia, 5016
Hospital Municipal Nuestra Sra. de Lujan
Luján, 6700
Centro de Investigacion Pergamino SA
Pergamino, B2700CPM
Sanatorio Parque de Rosario
Rosario, S2000DSV
Instituto Centralizado de Asistencia e Investigaci
Rosario, Santa Fe, S2000PBJ
CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica
San Juan, 5400
Centro de Investigaciones Médicas - CIM
San Juan Bautista, 1888
Centro de Investigaciones Reumatologicas Tucuman
San Miguel de Tucumán, 4000
Centro Médico Privado de Reumatología
San Miguel de Tucumán, T4000AXL
Canada17 sites
Royal Alexandra Hospital
Edmonton, Alberta, T5H 3V9
Arthur Karasik, MD
Etobicoke, Ontario, M9C 5N2
Charlton Medical Center
Hamilton, Ontario, L8N 1Y2
K-W Musculoskeletal Research
Kitchener, Ontario, N2M 5N6
St. Joseph's Hospital
London, Ontario, N6A 4V2
Credit Valley, Rheumatology
Mississauga, Ontario, L5M 2V8
Institut de Rhumatologie de Montreal
Montreal, Quebec, H2L 1S6
The Medical Arts Health Research Group
Powell River, British Columbia, V8A 3B6
Groupe de Recherche En Rhumatologie Et Maladies Osseuses
Québec, Quebec, G1V 3M7
Centre Re Recherche Saint-Louis
Québec, G1W 4R4
Chus Hopital Fleurimont
Sherbrooke, Quebec, J1H 5N4
Niagara Peninsula Arthritis Centre
St. Catharines, Ontario, L2N 7E4
Nexus Clinical Research Centre
St. John's, Newfoundland and Labrador, A1A 5E8
St. Clare'S Mercy Hospital
St. John's, Newfoundland and Labrador, A1C 5B8
Mount Sinai Hospital
Toronto, Ontario, M5G 1Z5
Centre de Recherche Musculo-Squelettique
Trois-Rivières, Quebec, G8Z 1Y2
Baker, Milton F.
Victoria, British Columbia, V8P 5P6
Russia17 sites
State institution of health care - Territorial Clinical Hospital
Barnaul, 656024
SEI of HPE "Altay State Medical University of Roszdrav"
Barnaul, 656038
Scientific and research medical complex Your Health
Kazan', 420097
SIH Kemerovo Regional Clinical Hospital
Kemerovo, 650002
City Hospital No.4
Moscow, 115093
Scient Res Inst Rheumat RAMS
Moscow, 115522
Moscow State Medical Stomatological University
Moscow, 121374
Head Clinical Hospital of Internal Affair Ministry of Russia
Moscow, 123060
MHI City Clinical Hospital#19
Novosibirsk, 630068
FSBI Scientific Research Institute of Clinical Immunology of SB of RAMS
Novosibirsk, 630099
Ryazan Regional Clinincal Cardiology Dispensary
Ryazan, 390026
Leningradskaya Regional Clinical Hospital; Rheumatology Dept
Saint Petersburg, 194291
State institution of healthcare "Regional hospital for war veterans"
Saratov, 410002
Stavropol State Medical Academy
Stavropol, 355017
Tomsk Regional Clinical Hospital
Tomsk, 634063
Voronezh Regional Clinical Hospital #1
Voronezh, 394066
MCHI Medical Sanitary Unit of Yaroslavl Diesel Apparatus Plant
Yaroslavl, 150007
France16 sites
CHU d'Amiens Hôpital Nord; Pharmacie Clinique
Amiens, 80054
Groupe Hospitalier Pellegrin
Bordeaux, 33000
CHU Hopital Gabriel Montpied
Clermont-Ferrand, 63003
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, 91106
CHU Grenoble Sud
Échirolles, 38434
Hôpital Edouard Herriot; Service de Rhumatologie
Lyon, 69003
CHR Orleans, Hopital Madeleine
Orléans, 45067
Hôpital Saint-Antoine; Service de Psychiatrie
Paris, 75571
Groupe Hospitalier Pitie-Salpetriere
Paris, 75651
Hopital Cochin; Gastro Enterologie
Paris, 75679
Hôpital Sud - CHU de Rennes
Rennes, 35033
Hôpital Victor Provo
Roubaix, 59056
CHU de Rouen, Hopital de Bois Guillaume; Service de Rhumatologie
Rouen, 76031
CHU Saint-Etienne, Hopital Bellevue
Saint-Etienne, 42055
Hôpital General - CHRU de Dijon
Strasbourg, 67098
Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O)
Toulouse, 31059
Germany16 sites
Charité Universitaetsmedizin Berlin, Campus Charité Mitte
Berlin, 10117
Schlosspark-Klinik
Berlin, 14059
Universitätsklinikum Köln, Klinik I für Innere Medizin
Cologne, 50937
Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden
Dresden, 01307
Universitätsklinikum Erlangen; Augenklinik
Erlangen, 91054
Praxisgemeinschaft Rheumatologie-Nephrologie Erlangen PGRN
Erlangen, 91056
Universitaetsklinikum Frankfurt
Frankfurt, 60528
Universitaetsklinikum Hamburg-Eppendorf; Medizinische Klinik Nephrologie/Rheumatologie
Hamburg, 20251
Schön Klinik Hamburg-Eilbek Klinik für Rheumatologie
Hamburg, 22081
Rheumazentrum Ruhrgebiet; St. Josefs-Krankenhaus
Herne, 44649
Gemeinschaftspraxis Dr. Von Hinueber/Dr. Demary; Rheumatologie
Hildesheim, 31134
Universitaetsklinikum Leipzig
Leipzig, 04103
Ludwig Maximilians; Universitaet
München, 80337
Praxiszentrum St. Bonifatius
München, 81541
Rheumatologische Gemeinschaftspraxis
Osnabrück, 49074
Evangelisches Fachkrankenhaus
Ratingen, 40882
Romania13 sites
Spitalul Clinic Judetean de Urgenta Brasov
Brasov, 500365
Spitalul Clinic Sf. Maria; Dept Interna si Reumatologie
Bucharest, 011172
Spitalul Clinic Dr. I Cantacuzino
Bucharest, 020475
Centrul de Boli Reumatismale Dr. Ioan Stoia
Bucharest, 020983
Medex SRL
Cluj-Napoca, 400130
Spitalul Clinic Judetean de Urgenta Cluj-Napoca, Clinica de Medicina Muncii
Cluj-Napoca, 400349
CMI Dr.Ciornohuz Adriana
Iași, 700127
Spitalul Clinic de Recuperare Iasi
Iași, 700656
Spitalul Municipal Ploiesti
Ploieşti, 100337
Spitalul Clinic Colentina
Sector 2, 020125
Spitalul Judetean de Urgenta Targoviste
Targoviste, 130083
Mediab SRL
Târgu Mureş, 540142
Spitalul Clinic Municipal de Urgenta Timisoara
Timișoara, 300194
United Kingdom13 sites
Selly Oak Hospital; Rheumatology Dept
Birmingham, B29 6JD
Addenbrooke's NHS Trust
Cambridge, CB2 0QQ
Cannock Chase Hospital; Rheumatology
Cannock, WS11 5XY
Russells Hall Hospital; Rheumatology Department
Dudley, DY1 2HQ
Leicester Royal Infirmary NHS Trust
Leicester, LE1 5WW
Royal London Hospital Outpatients Department
London, E1 1BB
Whipps Cross Hospital; Rheumatology Dept
London, E11 1NR
King'S College Hospital
London, SE5 9RS
Royal Victoria Infirmary
Newcastle upon Tyne, NE1 4LP
Salford Royal NHS Foundation Trust
Salford, M6 8HD
Southampton General Hospital; Rheumatology
Southampton, SO16 6YD
Southend Hospital; Rheumatology Department
Westcliffe-on-sea, SS0 0RY
Wrightington Hospital
Wrightington, WN6 9EP
Czechia12 sites
Fakultni nemocnice u sv. Anny v Brne
Brno, 656 91
Revmatologicka ambulance
Bruntál, 792 01
Revmatologicka Ambulance
Hlučín, 748 01
Interni a revmatologicka ordinace
Hostivice, 253 01
Revmatologicka a-interni ambulance
Kladno, 272 01
Revmatologie MUDr. Klara Sirova s.r.o.
Ostrava - Moravska Ostrava, 702 00
Revmatologicky Ustav
Prague, 128 50
Revmatologicka ambulance
Prague, 140 00
Fakultni Thomayerova nemocnice s poliklinikou
Prague, 140 59
Artroscan s.r.o.
Sokolov, 356 01
Revmatologicka Ambulance-Terezin
Terezín, 411 55
PV - Medical, s.r.o.
Zlín, 748 01
Spain12 sites
Hospital de Cruces; Servicio de Reumatologia
Barakaldo, Vizcaya, 48903
Hospital Universitario Basurto
Bilbao, Vizcaya, 48013
Hospital General de Castellon; Servicio de Reumatologia
Castellon, Castellon, 12004
Hospital Gregorio Marañon
Madrid, 28007
Hospital Regional Universitario Carlos Haya
Málaga, Malaga, 29009
Hospital de Merida ;Servicio de Reumatologia
Mérida, Badajoz, 06800
Hospital Universitario de Canarias
S. Cristobal de La Laguna, Tenerife, 38320
Corporacio Sanitaria Parc Tauli
Sabadell, Barcelona, 08208
Hospital Infanta Sofia; Servicio de Reumatologia
San Sebastián de los Reyes, Madrid, 28702
Hospital Clinico Universitario de Santiago
Santiago de Compostela, La Coruña, 15706
Hospital Universitario Virgen Macarena
Seville, Sevilla, 41071
Hospital Sierrallana
Torrelavega, Cantabria, 39300
Hungary11 sites
Országos Fizioterápiás És Reumatológiai Intézet; I. Reumatológiai És Metabolikus Osteológiai Osztály
Budapest, 1027
Clinexpert Egeszsegugyi Szolgaltato es Kereskedelmi Kft
Budapest, 1033
Obudai Egeszsegugyi Centrum Kft.
Budapest, 1036
Synexus Magyarorszag Kft
Budapest, 1036
Debreceni Egyetem, Klinikai Kozpont, Tudogyogyaszati Klinika
Debrecen, 4032
Markhot Ferenc Eu. Szolg. Nonprofit Kiem. Kozh. Kft.
Eger, 3300
Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza
Gyula, 5700
Varosi Korhaz-Rendelointezet
Mór, 8060
Fejer Megyei Szent Gyorgy Korhaz
Székesfehérvár, 8000
Clinfan Szolgaltato Kft.
Szekszárd, 7100
Zala Megyei Korhaz; Reumatologia
Zalaegerszeg, 8901
Italy11 sites
Ospedale La Colletta
Arenzano, Liguria, 16011
Ospedali Riuniti di Bergamo
Bergamo, Lombardy, 24128
Presidio Ospedaliero Vittorio Emanuele
Catania, Sicily, 95124
Azienda Ospedaliera Universitaria Careggi
Florence, Tuscany, 50141
Azienda Ospedaliero Universitaria San Martino
Genoa, Liguria, 16132
Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia
Milan, Lombardy, 20162
Azienda Ospedaliera A. Cardarelli
Naples, Campania, 80131
Ospedale San Giovanni Bosco; Divisione di Reumatologia
Naples, Campania, 80144
Ospedale Misericordia e Dolce
Prato, Tuscany, 59100
Fondazione Salvatore Maugeri IRCCS; Istituto Scientifico di Riabilitazione di Telese
Telese Terme, Campania, 82037
Ospedale Di Circolo E Fondazione Macchi
Varese, Lombardy, 21100
Poland11 sites
Szpital Uniwersytecki; nr 2 im. Dr J. Biziela
Bydgoszcz, 85-168
Wojewodzki Szpital Zespolony w Elblagu
Elblag, 82-300
Szpital Specjalistyczny Im J. Dietla Malopolskie Centrum Reumat; Oddzial Rumatologii
Krakow, 30-119
Szpital Specjalistyczny im. J. Dietla
Krakow, 31-121
NZOZ REUMED Sp. z o.o.
Lublin, 20-607
Lecznica MAK-MED NZOZ
Nadarzyn, 05-830
SP Szpital Kliniczny nr 1 Pomorskiej Akademii Medycznej im. prof. Tadeusza Sokolowskiego
Szczecin, 71-252
Slaski Szpital Reumatologiczno; Rehabilitacyjny; Iii Oddzial Reumatologiczny
Ustroń, 43-450
Rheuma Medicus Zaklad Opieki Zdrowotnej
Warsaw, 02-118
ARS Rheumatica Sp.z o. o
Warsaw, 02-653
Akademicki Szpital Kliniczny im. Jana Mikulicza Radeckiego
Wroclaw, 50-556
Chile9 sites
Hospital San Juan de Dios La Serena
La Serena, 1700000
Centro Medico Prosalud
Santiago, 7500000
Interin
Santiago, 7500035
Centro de Estudios Reumatológicos
Santiago, 7501126
Hospital Clinico Pontificia Universidad Catolica de Chile
Santiago, 8320112
Centro de Investigacion Clinica del Sur
Temuco, 4780000
Clinica Alemana de Temuco
Temuco, 4780000
Hospital Clinico Viña del Mar- Oncovida
Viña del Mar, 2520612
Centro de Estudios Clinicos V Region Limitada
Viña del Mar
Greece7 sites
Laiko General Hospital Athen
Athens, 115 27
Euroclinic of Athens; Internal Medicine & Immunology Dept.
Athens, 15121
University General Hospital of Heraklion
Crete, 71110
University General Hospital of Larissa; Rheumatology Unit
Larissa, 411 10
General Hospital of Thessaloniki Hippokration
Thessaloniki, 54 642
Euromedica Kyanous Stavros General Hospital
Thessaloniki, 546 36
424 Military Training Hospital-Egnatia
Thessaloniki
India7 sites
Shalby Hospital Limited
Ahmedabad, Gujarat, 380015
Vedanta Institute; Medical Sciences
Ahmedabad, 380009
Manipal Hospital
Bangalore, 560017
St.John's Medical College Hospital
Banglore, 560034
Arthritis Super Speciality Centre
Hubli, 580020
Care Institute of Medical Sciences
Hyderabad, 500034
Jasleen Hospital
Nagpur, 440010
Latvia7 sites
L.Krumina GP practice
Bauska, 3901
Daugavpils Regional Hospital
Daugavpils, 5417
D.Saulite-Kandevica Private Practice
Liepāja, 3400
Clinic ORTO
Riga, 1005
Private Practice EHOKG
Riga, 1021
Riga East Clinical University Hospital; Clinic Gailezers
Riga, LV 1002
P. Stradins Clinical University Hospital
Riga, LV-1002
Ecuador6 sites
Hospital Clínica Santa Inés
Cuenca, 101168
Centro de Reumatología y Rehabilitación
Guayaquil, 593
OMNI Hospital
Guayaquil, 593
Centro Medico Alcivar 4
Guayaquil, EC090114
Centro Medico Picasso
Quito, 005932
Novaclinica Santa Cecilia; Reumatology
Quito, EC170517
Malaysia6 sites
Hospital Pulau Pinang
George Town, Pulau Pinang, 10990
Hospital Raja Permaisuri Bainun
Ipoh, Perak, 30990
Hospital Selayang
Kuala Lumpur, 68100
Sunway Medical Centre
Kuala Selangor, Selangor, 46150
Sime Darby Medical Centre
Kuala Selangor, Selangor, 47500
Hospital Umum Sarawak
Kuching, 93586
Austria5 sites
Lkh-Univ. Klinikum Graz
Graz, 8036
Landesklinikum Weinviertel Stockerau; Rheumatologie
Stockerau, 2000
Medizinische Universität Wien
Vienna, 1090
Rheuma-Zentrum Favoriten Wien
Vienna, 1100
Krankenhaus Hietzing; 2.Med.Abteilung, Pav.3A
Vienna, 1130
Belgium5 sites
CHU St Pierre (St Pierre)
Brussels, 1000
Cliniques Universitaires St-Luc
Brussels, 1200
AZ Groeninge (Vercruysselaan)
Kortrijk, 8500
CHU Sart-Tilman
Liège, 4000
ZNA Jan Palfijn
Merksem, 2170
Croatia5 sites
General Hospital Karlovac
Karlovac, 47000
Special Hospital for Medical Rehabilitation
Krapinske Toplice, 49217
Clinical Hospital Centre Rijeka; Department of Rheumatology and Clinical Immunology
Rijeka, 51000
Clinical Hospital Centre Zagreb
Zagreb, 10000
Universtiy Hospital Dubrava
Zagreb, 10000
Israel5 sites
Barzilai Medical Center
Ashkelon, 78278
Assaf Harofeh Medical Center
Beer Yaacov, 6093000
The Lady Davis Carmel Medical Center
Haifa, 34362
Chaim Sheba Medical Center; Rheumatology
Ramat Gan, 5262000
Tel-Aviv Sourasky Medical Center
Tel Aviv, 64239
Lithuania5 sites
Alytus Regional S. Kudirkos Hospital, Public Institution
Alytus, 62114
Klaipeda Seamen's Hospital, Public Institution
Klaipėda, 92288
Klaipeda University Hospital; Public Institution
Klaipėda, 92288
Siauliai Republican Hospital Public Institution
Šiauliai, 76231
Vilnius District Central Outpatient Clinic, Public Institution
Vilnius, 06122
Philippines5 sites
Cebu Doctors' University Hospital- North General Hospital
Cebu City, 6000
Chong Hua Hospital, Cebu City
Cebu City, 6000
St. Paul Hospital; Arthritis Center
Iloilo City, 5000
Mary Mediatrix Medical Center
Lipa City, 4217
Makati Medical Center
Makati City, 1229
Bosnia and Herzegovina4 sites
University Clinical Center of the Republic of Srpska
Banja Luka, 78000
University Clinic Ctr Sarajevo
Sarajevo, 71 000
General Hospital Prim.dr.Abdulah Nakas
Sarajevo, 71000
Uni Hospital Center Tuzla
Tuzla, 75000
Netherlands4 sites
Jan Van Breemen Instituut
Amsterdam, 1056 AB
Albert Schweitzer Ziekenhuis ; Dordwijk
Dordrecht, 3318AT
Franciscus Ziekenhuis
Roosendaal, 4708 AE
Vlietland Hospital
Schiedam, 3118 JH
Serbia4 sites
Institute of Rheumatology
Belgrade, 11000
Military Medical Academy
Belgrade, 11040
Clinical Center Bezanijska Kosa
Belgrade, 11070
Institute of Rheumatology and Cardiovascular Diseases; Rheumatology
Niška Banja, 18205
South Africa4 sites
Groote Schuur Hospital; Rheumatology Unit
Cape Town, 7925
Chris Hani Baragwanath Hospital; Rheumatology Department
Diepkloof, 1862
Charlotte Maxeke Academic Hospital
Johannesburg, 2193
University of Pretoria; Clinical Trial Unit
Pretoria, 0002
Turkey (Türkiye)4 sites
Akdeniz Univesity Medical Faculty
Antalya, 07058
Trakya University Medical Faculty
Edirne, 22030
Ataturk University Med Faculty
Erzurum, 25050
Karadeniz Tecnical Uni. Med. Fac.
Trabzon, 61100
About this study
Official title: A Clinical Outcomes Study to Evaluate the Effects of IL-6 Receptor Blockade With Tocilizumab (TCZ) in Comparison With Etanercept (ETA) on the Rate of Cardiovascular Events in Patients With Moderate to Severe Rheumatoid Arthritis (RA)
This randomized, open-label, parallel-group, multicenter study will evaluate the rate of cardiovascular events with tocilizumab in comparison to etanercept in participants with rheumatoid arthritis (RA). Participants will be randomized to receive intravenous (IV) 8 milligrams per kilogram (mg/kg) tocilizumab every 4 weeks or subcutaneous 50 milligrams (mg) etanercept weekly, with or without non-biologic disease-modifying anti-rheumatic drug (DMARD).
- Conditions
- Rheumatoid Arthritis
- Being tested
- Etanercept, Tocilizumab
- Medical subject headings
- Arthritis, Rheumatoid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EtanerceptDrug
Participants will receive 50 mg etanercept subcutaneously weekly until switch to another RA therapy or up to 4.9 years.
TocilizumabDrug
Also called Actemra
Participants will receive 8 mg/kg tocilizumab IV every 4 weeks until switch to another RA therapy or up to 4.9 years.
| Study group | Role | What they receive |
|---|---|---|
| Etanercept | Active comparator | Not described Receives: Drug: Etanercept |
| Tocilizumab | Experimental | Not described Receives: Drug: Tocilizumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to First Cardiovascular (CV) Events Adjudication Committee (EAC) (CV-EAC) Adjudicated Event
Prospective comparison of time to first occurrence of any component of the composite of CV death (including events adjudicated as 'Undetermined Cause of Death'), non-fatal myocardial infarction, or non-fatal stroke.
Measured: From baseline up to 4.9 years
Percentage of Patients Reporting a Cardiovascular (CV) Events Adjudication Committee (EAC) (CV-EAC) Adjudicated Event
Percentage of patients reporting any component of the composite of CV death (including events adjudicated as 'Undetermined Cause of Death'), non-fatal myocardial infarction, or non-fatal stroke
Measured: From baseline up to 4.9 years
Time to First CV-EAC Adjudicated Event - Sensitivity Analysis
Prospective comparison of time to first occurrence of any component of the composite of CV death (including events adjudicated as 'Undetermined Cause of Death'), non-fatal myocardial infarction, or non-fatal stroke - Sensitivity Analysis
Measured: From Baseline up to 4.9 years
Percentage of Patients With a CV-EAC Adjudicated Event - Sensitivity Analysis
Percentage of patients with any component of the composite of CV death (including events adjudicated as 'Undetermined Cause of Death'), non-fatal myocardial infarction, or non-fatal stroke - Sensitivity Analysis
Measured: From Baseline up to 4.9 years
Time to First CV-EAC Adjudicated Event Excluding Undetermined Cause of Death - Sensitivity Analysis
Prospective comparison of time to first occurrence of any component of the composite of CV death (excluding events adjudicated as 'Undetermined Cause of Death'), non-fatal myocardial infarction, or non-fatal stroke - Sensitivity Analyses
Measured: From baseline up to 4.9 years
Percentage of Patients With a CV-EAC Adjudicated Event Excluding Undetermined Cause of Death - Sensitivity Analysis
Percentage of patients with any component of the composite of CV death (excluding events adjudicated as 'Undetermined Cause of Death'), non-fatal myocardial infarction, or non-fatal stroke - Sensitivity Analyses
Measured: From baseline up to 4.9 years
Time to First CV-EAC Adjudicated Event Before Last Direct Contact Date
Prospective comparison of time to first occurrence of any component of the composite of CV death (including events adjudicated as 'Undetermined Cause of Death'), non-fatal myocardial infarction, or non-fatal stroke before last direct contact date (i.e., latest date of visit, IVRS call, or site call).
Measured: From Baseline up to 4.9 years
Percentage of Participants With a CV-EAC Adjudicated Event Before Last Direct Contact Date
Percentage of participants with any component of the composite of CV death (including events adjudicated as 'Undetermined Cause of Death'), non-fatal myocardial infarction, or non-fatal stroke before last direct contact date (i.e., latest date of visit, IVRS call, or site call).
Measured: From Baseline up to 4.9 years
Secondary outcomes (10)
The Time to First Occurrence of an Expanded CV Composite Endpoint
Prospective comparison of the time to first ccurrence of the expanded composite endpoint. The expanded composite endpoint is defined as the CV composite of the primary endpoint with the addition of non-elective coronary revascularization procedures and hospitalization for unstable angina.
Measured: From baseline up to 4.9 years
Percentages of Participants With an Expanded CV Composite Endpoint
Percentages of participants with the expanded CV composite endpoint. The expanded composite endpoint is defined as the CV composite of the primary endpoint with the addition of non-elective coronary revascularization procedures and hospitalization for unstable angina.
Measured: From baseline up to 4.9 years
Time to First Occurrence of Individual Component of Primary Endpoint: Non-fatal Myocardial Infarction
Prospective comparison of time to first occurrence of Individual component of primary endpoint: non-fatal Myocardial Infarction
Measured: From baseline up to 4.9 years
Percentage of Patients With Individual Component of Primary Endpoint: Non-fatal Myocardial Infarction
Percentage of patients reporting Individual component of primary endpoint: non-fatal Myocardial Infarction
Measured: From baseline up to 4.9 years
Time to First Occurrence of Individual Component of Primary Endpoint: Cardiovascular Death
Prospective comparison of time to first occurrence of Individual component of primary endpoint: cardiovascular death
Measured: From baseline up to 4.9 years
Percentage of Patients With Individual Component of Primary Endpoint: Cardiovascular Death
Percentage of patients reporting Individual component of primary endpoint: cardiovascular death
Measured: From baseline up to 4.9 years
Time to First Occurrence of Individual Component of Primary Endpoint: Non-fatal Stroke
Prospective comparison of time to first occurrence of Individual component of primary endpoint: non-fatal stroke
Measured: From baseline up to 4.9 years
Percentage of Patients With Individual Component of Primary Endpoint: Non-fatal Stroke
Measured: From baseline up to 4.9 years
Time to First Occurrence of Individual Component of Primary Endpoint: All-cause Mortality
Prospective comparison of time to first occurrence of Individual component of primary endpoint: All-cause mortality
Measured: From baseline up to 4.9 years
Percentage of Patients With Individual Component of Primary Endpoint: All-cause Mortality
Percentage of patients reporting Individual component of primary endpoint: All-cause mortality
Measured: From baseline up to 4.9 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Apr 2011 (estimated)
- Study start2 Aug 2011
- Primary completion25 Mar 2016
- Study completion25 Mar 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Rheumatoid ArthritisStudies of the same condition, open and under way.
- More trials run by Hoffmann-La RocheThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 3,080 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Trials, Study director, Hoffmann-La Roche
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01331837
- Sponsor's protocol ID
- WA25204
- Other IDs
- 2010-020065-24
- Status last verified
- Jun 2017
- First submitted
- 7 Apr 2011
- Last updated
- 13 Jul 2017
- Results posted
- Yes, on ClinicalTrials.gov
Publications
Giles JT, Sattar N, Gabriel S, Ridker PM, Gay S, Warne C, Musselman D, Brockwell L, Shittu E, Klearman M, Fleming TR. Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial. Arthritis Rheumatol. 2020 Jan;72(1):31-40. doi: 10.1002/art.41095.
PubMed 31469238
Study at a glance
From the registry record, last updated by the sponsor on 13 Jul 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Outcomes Study to Evaluate the Effects of IL-6 Receptor Blockade With Tocilizumab (TCZ) in Comparison With Etanercept (ETA) on the Rate of Cardiovascular Events in Patients With Moderate to Severe Rheumatoid Arthritis (RA)
- ClinicalTrials.gov ID
- NCT01331837
- Acronym / sponsor ID
- WA25204
- Conditions
- Rheumatoid Arthritis
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 3,080 participants (actual)
- Lead sponsor
- Hoffmann-La RocheIndustry (pharma, biotech, devices)
- Study start
- 2 Aug 2011 (actual)
- Primary completion
- 25 Mar 2016 (actual)
- Study completion
- 25 Mar 2016 (actual)
- First posted
- 8 Apr 2011 (estimated)
- Results
- Posted 13 Jul 2017
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized, open-label, parallel-group, multicenter study will evaluate the rate of cardiovascular events with tocilizumab in comparison to etanercept in participants with rheumatoid arthritis (RA). Participants will be randomized to receive intravenous (IV) 8 milligrams per kilogram (mg/kg) tocilizumab every 4 weeks or subcutaneous 50 milligrams (mg) etanercept weekly, with or without non-biologic disease-modifying anti-rheumatic drug (DMARD).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Etanercept | Active comparator | Drug: Etanercept |
| Tocilizumab | Experimental | Drug: Tocilizumab |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Participants with moderate to severe RA of greater than or equal to (>=6) months duration
- Inadequate response to at least one non-biologic DMARD
- Positive for Rheumatoid Factor (RF) and/or anti-cyclic citrullinated peptide (CCP) antibodies at screening
- Have C-reactive protein (CRP) greater than (>) 0.3 milligrams per deciliter (mg/dL) at screening or at the baseline visit
- Swollen joint count (SJC) >=8 (66 joint count) and tender joint count (TJC) >= 8 (68 joint count) during screening or at the baseline visit
Key exclusion criteria (26 listed)
- Major surgery (including joint surgery or coronary revascularization) within 8 weeks prior to screening or planned major surgery within 1 year of study start
- Rheumatic autoimmune disease other than RA
- History of or current inflammatory joint disease other than RA
- Current or recent (within past 3 months) evidence of serious uncontrolled concomitant cardiovascular or cerebrovascular disease (myocardial infarction, revascularization, stroke, transient ischemic attack, or acute coronary syndrome)
- Current or previous (within the past 2 years) evidence of serious uncontrolled concomitant pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine (including uncontrolled diabetes mellitus) or gastrointestinal disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EtanerceptParticipants will receive 50 mg etanercept subcutaneously weekly until switch to another RA therapy or up to 4.9 years. | Drug | Etanercept |
| TocilizumabAlso: ActemraParticipants will receive 8 mg/kg tocilizumab IV every 4 weeks until switch to another RA therapy or up to 4.9 years. | Drug | Tocilizumab |
Primary outcome
Time to First Cardiovascular (CV) Events Adjudication Committee (EAC) (CV-EAC) Adjudicated Event
Time frame: From baseline up to 4.9 years
Prospective comparison of time to first occurrence of any component of the composite of CV death (including events adjudicated as 'Undetermined Cause of Death'), non-fatal myocardial infarction, or non-fatal stroke.
Percentage of Patients Reporting a Cardiovascular (CV) Events Adjudication Committee (EAC) (CV-EAC) Adjudicated Event
Time frame: From baseline up to 4.9 years
Percentage of patients reporting any component of the composite of CV death (including events adjudicated as 'Undetermined Cause of Death'), non-fatal myocardial infarction, or non-fatal stroke
Time to First CV-EAC Adjudicated Event - Sensitivity Analysis
Time frame: From Baseline up to 4.9 years
Prospective comparison of time to first occurrence of any component of the composite of CV death (including events adjudicated as 'Undetermined Cause of Death'), non-fatal myocardial infarction, or non-fatal stroke - Sensitivity Analysis
Percentage of Patients With a CV-EAC Adjudicated Event - Sensitivity Analysis
Time frame: From Baseline up to 4.9 years
Percentage of patients with any component of the composite of CV death (including events adjudicated as 'Undetermined Cause of Death'), non-fatal myocardial infarction, or non-fatal stroke - Sensitivity Analysis
Time to First CV-EAC Adjudicated Event Excluding Undetermined Cause of Death - Sensitivity Analysis
Time frame: From baseline up to 4.9 years
Prospective comparison of time to first occurrence of any component of the composite of CV death (excluding events adjudicated as 'Undetermined Cause of Death'), non-fatal myocardial infarction, or non-fatal stroke - Sensitivity Analyses
Percentage of Patients With a CV-EAC Adjudicated Event Excluding Undetermined Cause of Death - Sensitivity Analysis
Time frame: From baseline up to 4.9 years
Percentage of patients with any component of the composite of CV death (excluding events adjudicated as 'Undetermined Cause of Death'), non-fatal myocardial infarction, or non-fatal stroke - Sensitivity Analyses
Time to First CV-EAC Adjudicated Event Before Last Direct Contact Date
Time frame: From Baseline up to 4.9 years
Prospective comparison of time to first occurrence of any component of the composite of CV death (including events adjudicated as 'Undetermined Cause of Death'), non-fatal myocardial infarction, or non-fatal stroke before last direct contact date (i.e., latest date of visit, IVRS call, or site call).
Percentage of Participants With a CV-EAC Adjudicated Event Before Last Direct Contact Date
Time frame: From Baseline up to 4.9 years
Percentage of participants with any component of the composite of CV death (including events adjudicated as 'Undetermined Cause of Death'), non-fatal myocardial infarction, or non-fatal stroke before last direct contact date (i.e., latest date of visit, IVRS call, or site call).
10 secondary outcomes
The Time to First Occurrence of an Expanded CV Composite Endpoint
Time frame: From baseline up to 4.9 years
Percentages of Participants With an Expanded CV Composite Endpoint
Time frame: From baseline up to 4.9 years
Time to First Occurrence of Individual Component of Primary Endpoint: Non-fatal Myocardial Infarction
Time frame: From baseline up to 4.9 years
Percentage of Patients With Individual Component of Primary Endpoint: Non-fatal Myocardial Infarction
Time frame: From baseline up to 4.9 years
Time to First Occurrence of Individual Component of Primary Endpoint: Cardiovascular Death
Time frame: From baseline up to 4.9 years
Percentage of Patients With Individual Component of Primary Endpoint: Cardiovascular Death
Time frame: From baseline up to 4.9 years
Time to First Occurrence of Individual Component of Primary Endpoint: Non-fatal Stroke
Time frame: From baseline up to 4.9 years
Percentage of Patients With Individual Component of Primary Endpoint: Non-fatal Stroke
Time frame: From baseline up to 4.9 years
Time to First Occurrence of Individual Component of Primary Endpoint: All-cause Mortality
Time frame: From baseline up to 4.9 years
Percentage of Patients With Individual Component of Primary Endpoint: All-cause Mortality
Time frame: From baseline up to 4.9 years
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jul 2017.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 31469238Giles JT, Sattar N, Gabriel S, Ridker PM, Gay S, Warne C, Musselman D, Brockwell L, Shittu E, Klearman M, Fleming TR. Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial. Arthritis Rheumatol. 2020 Jan;72(1):31-40. doi: 10.1002/art.41095.
Related trials for Rheumatoid Arthritis
RecruitingPhase 2
Study of PTC844 in Participants With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Not yet recruitingPhase 1
An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
Rheumatoid Arthritis and Systemic Lupus Erythematosus
Not yet recruitingPhase 1
R-2487 in Patients With Sjogren's Syndrome (SjD)
Sjogren's Syndrome, Sjögren
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Active, not recruitingPhase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Trials study director
Hoffmann-La Roche
428 sites in 31 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Etanercept and Tocilizumab in people with Rheumatoid Arthritis, run by Hoffmann-La Roche at 428 sites in 31 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Jul 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 428 sites in United States, Mexico, Argentina, Canada, Russia and 26 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 13 Jul 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to First Cardiovascular (CV) Events Adjudication Committee (EAC) (CV-EAC) Adjudicated Event (time frame: From baseline up to 4.9 years). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01331837, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2017.